World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
43
Citations
11817
World Ranking
5197
National Ranking
6

Andrzej Horban publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Andrzej Horban sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 228 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Andrzej Horban D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Andrzej Horban sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 43 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Andrzej Horban is affiliated with the Medical University of Warsaw in Poland. Their research primarily focuses on medicine, with a substantial body of work in infectious diseases, as well as significant contributions to epidemiology, hepatology, public health, and virology.

The main topics covered in their research include:

  • HIV/AIDS Research and Interventions
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Hepatitis C virus research
  • HIV, Drug Use, Sexual Risk
  • Long-Term Effects of COVID-19
  • HIV Research and Treatment

Notable recent publications demonstrate a focus on the management and clinical aspects of infectious diseases, particularly related to COVID-19 and HIV. Some recent papers include:

  • "HIV care in times of the COVID-19 crisis - Where are we now in Central and Eastern Europe?", 2020, International Journal of Infectious Diseases
  • "Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021", 2021, Polskie Archiwum Medycyny Wewnętrznej
  • "Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists", 2020, Polskie Archiwum Medycyny Wewnętrznej
  • "Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020", 2020, Polskie Archiwum Medycyny Wewnętrznej
  • "Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study", 2020, Expert Review of Anti-infective Therapy

Frequent co-authors in Andrzej Horban's publications include Justyna Kowalska, Agata Skrzat-Klapaczyńska, Robert Flisiak, Krzysztof Tomasiewicz, and Dorota Zarębska-Michaluk. Collaboration with these researchers has resulted in numerous studies exploring epidemiological and clinical aspects of infectious diseases.

Their work has appeared repeatedly in several key scientific journals and venues, including:

  • Polskie Archiwum Medycyny Wewnętrznej
  • HIV Medicine
  • Journal of Clinical Medicine
  • Vaccines
  • Przeglad Epidemiologiczny

Andrzej Horban's publication record highlights a sustained emphasis on infectious diseases, especially HIV/AIDS and COVID-19, with a blend of clinical research, management recommendations, and public health implications. Their contributions span a broad range of topics within medicine, supporting advancements in understanding and responding to infectious threats.

Best Publications

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Roy M. Gulick;Jacob Lalezari;James Goodrich;Nathan Clumeck

  • Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management

    Annemarie M. J. Wensing;David A. van de Vijver;Gioacchino Angarano;Birgitta Åsjö

  • Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy

    Jiirgen K. Rockstroh;Amanda Mocroft;Vincent Soriano;Cristina Tural

  • Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

    Yun-Fan Liaw;I-Shyan Sheen;Chuan-Mo Lee;Ulus Salih Akarca

  • Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

    Xavier Forns;Eric Lawitz;Stefan Zeuzem;Ed Gane

  • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

    Frank van Leth;Prahpan Phanuphak;Erik Stroes;Brian Gazzard

  • Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

    David A Cooper;Jayvant Heera;James Goodrich;Margaret Tawadrous

  • The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

    Robert Flisiak;Andrzej Horban;Philippe Gallay;Michael Bobardt

  • Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe

    Jurgen Vercauteren;Annemarie M. J. Wensing;David A. M. C. van de Vijver;Jan Albert

  • The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naive hepatitis C patients.

    Robert Flisiak;Saya V. Feinman;Maciej Jablkowski;Andrzej Horban

  • A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.

    Remko Van Leeuwen;Christine Katlama;Robert Murphy;Kathleen Squires

  • Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes.

    Tomasz Laskus;Marek Radkowski;Andrzej Piasek;Marek Nowicki

  • The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

    Jose R Arribas;Andrzej Horban;Jan Gerstoft;Gerdt Fätkenheuer

  • Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B

    Scott Fung;Peter Kwan;Milotka Fabri;Andrzej Horban

  • Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results

    Jose Gatell;Dominique Salmon Ceron;Adriano Lazzarin;Eric Van Wijngaerden

  • Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus.

    Kazima Saira;Xudong Lin;Jay V. DePasse;Rebecca Halpin

  • Acute hepatitis C in HIV-infected individuals : recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel

    Matthieu Albert;Jose Benito;Sanjay Bhagani;Christoph Boesecke

  • Updated European recommendations for the clinical use of HIV drug resistance testing

    A. M. Vandamme;A. Sönnerborg;M. Ait-Khaled;J. Albert

  • Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

    Jean-François Delfraissy;Philippe Flandre;Constance Delaugerre;Jade Ghosn

  • Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

    L. Marije Hofstra;Nicolas Sauvageot;Jan Albert;Jan Albert;Ivailo Alexiev

  • Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.

    Stuart C. Gordon;Zahary Krastev;Andrzej Horban;Jörg Petersen

  • High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.

    Patrick Marcellin;Hugo Cheinquer;Manuela Curescu;Geoffrey M. Dusheiko

  • Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group

    A. Mocroft;B. Ledergerber;J. P. Viard;S. Staszewski

  • Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

    R. Flisiak;E. Janczewska;M. Wawrzynowicz-Syczewska;J. Jaroszewicz

Frequent Co-Authors

Tomasz Laskus
Tomasz Laskus Medical University of Warsaw
Stanislas Pol
Stanislas Pol Université Paris Cité
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Graham R. Foster
Graham R. Foster Queen Mary University of London
Charles A. Boucher
Charles A. Boucher Erasmus University Rotterdam
José M. Gatell
José M. Gatell University of Barcelona
Anders Sönnerborg
Anders Sönnerborg Karolinska Institute
Jan Albert
Jan Albert Karolinska Institute
Anne-Mieke Vandamme
Anne-Mieke Vandamme Rega Institute for Medical Research
Annemarie M. J. Wensing
Annemarie M. J. Wensing Utrecht University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to diverse career opportunities, many of which can be enhanced through related online degrees. For instance, those interested in healthcare support roles might explore becoming a child life specialist, where understanding biological processes can improve patient care. Understanding best associate degrees for felons is also crucial, as microbiology-related programs may be available that offer a second chance for individuals with records to build a successful career.

Additionally, combining microbiology knowledge with healthcare can lead to specialized paths such as a functional medicine nurse practitioner programs. These roles integrate biology with patient care, making them highly relevant for microbiology graduates.

For those interested in the administrative side of healthcare, pursuing certification in medical coding is another viable option. Understanding the cpc salary and career paths can help microbiology graduates diversify their skill set and improve job prospects in health information management.

Best Scientists Citing Andrzej Horban

Trending Scientists

Recently Published Articles